澳门永利娱场官方网-Apple App Store

NEWS

  • 2022/07/14 PhIRDA

    Chinese First Base Editing Tool Authorized by Overseas Patent

    tBE(transformer Base Editor), developed by the scientific co-founders of CorrectSequence Therapeutics (Correctseq), is authorized by USPTO (United States Patent and Trademark Office) formally. It’s th

    Details

  • 2022/07/13 Correctseq

    CorrectSequence's Base Editing Tool Authorized by Overseas Patent

    July 13, 2022(USA time), tBE(transformer Base Editor), developed by the scientific co-founders of CorrectSequence Therapeutics(Correctseq), is authorized by USPTO formally(United States Patent and Trademark Office). It’s the Chinese first base editing tool authorized by overseas patents. Correctseq has got the worldwide exclusive license of tBE from ShanghaiTech University, becoming the exclusive biopharmaceutical company that owns the global rights and interests of the underlying platform-based base editing system patent. The First IND pipeline for thalassemia of Correctseq is well underway, using tBE to create a creative base editing therapy. Correctseq is the Chinese first biopharmaceutical company which transforms the Chinese self-developed base editing tool into a creative base editing therapy. Correctseq has already got the worldwide exclusive license of eBE, which is the first base editing tool authorized by Chinese patents. At the same time, Correctseq has applied PCT for several base editing tools.

    Details

  • 2022/07/03 Correctseq

    Prof. Bei Yang, Co-founder of Correctseq, Participates in Antigen & Antibody Discovery and Precision Medicine Conference and Makes a Speech

    July 2, 2022, Prof. Bei Yang, co-founder of CorrectSequence Therapeutics (Correctseq), participated in Antigen & Antibody Discovery and Precision Medicine Conference and made a speech titled “Antigenic Mapping by HDX-MS Reveals Sites of Vulnerability on α-HCoVs Spike Protein”. 3 academicians, 10 experts shared their newest research in the field of antigen & antibody. The conference was held online and attracted 6600 attendees.

    Details

  • 2022/06/17 Correctseq

    Correctseq Gets Prize of ”Top 10 Gene Therapy Companies of 2022 Future Healthcare VB100-Best Performing Companies in Value Fields”

    June 15, 2022, Correctseq got prize of “Top 10 Gene Therapy Companies of 2022 Future Healthcare VB100-Best Performing Companies in Value Fields” from VBDATA.CN, which held a conference titled“2022 Future Healthcare VB100”from June 14 to 18, 2022. Correctseq is considered as the most potential company in the gene therapy fields because of its innovative gene editing technology by investors and medias.

    Details

  • 2022/06/16 Correctseq

    Correctseq Gets Prize of ”2022 Top 50 Biotech Innovation Companies”

    June 15, 2022, Correctseq got prize of “2022 Top 50 Biotech Innovation Companies” from KPMG. On the prize list, more than half of companies have 5 years histories, 89% companies have more than 3 years histories, only 4 companies have less than 2 years histories and Correctseq is one of them. Correctseq is evaluated to be the most potential company in the gene therapy fields because of its innovative gene editing technology.

    Details

  • 2022/05/01 Correctseq

    Dr. Gao Serves as a Distinguished Adviser of Quality Department of Correctseq to Accelerate the Pipeline Advances and Quality System Establishment

    On May 1, 2022, CorrectSequence Therapeutics (Correctseq), a pioneer gene editing biotechnology company, announced that Dr. Guang Gao was invited to serve as a long-term special consultant for global quality standards, to guide the global application of Correctseq R&D pipeline and the establishment of global quality systems in line with China, USA and European standards.

    Details

  • 2022/04/26 Correctseq

    Prof. Hao Yin, Co-founder of Correctseq, Participates in 2022 Simcere Innovation Forum and Makes a Speech

    On April 25, 2022, Prof. Hao Yin, Co-founder of CorrectSequence Therapeutics (Correctseq) was invited to attend 2022 Simcere Innovation Forum which was held in Nanjing and Boston at the same time, and made a speech titled” CRISPR-based gene therapy and nucleic acids detection”. The experts from home and abroad online and offline discussed the newest technologies of biomedicine field on the forum, which abstracted about 1,500 medicine young scholars.

    Details

  • 2021/12/08 Correctseq

    Dr. Xiaodun Mou Joins CorrectSequence Therapeutics as CEO

    CorrectSequence Therapeutics (Correctseq), founded in 2020, has announced the appointment of Dr. Xiaodun (Susan) Mou as the Chief Executive Officer (CEO), in charge of general operation of the company. Correctseq is a cutting-edge biotechnology company leading the evolution of new gene editing technologies with a special focus on base editing for the permanent cure of genetic diseases to benefit global patients. Together with its accomplishments of series A financial raising, the opening of new research laboratories at Starthub Incubator in Shanghai Zhangjiang Innovation Center, the onboarding of Dr. Mou as CEO will drive the development of Correctseq to the new era. Dr. Mou will lead the clinical application of base editing technology, the expansion of therapeutic pipelines, the establishment of global standard CMC platform and the cGMP manufacturing of gene editing medicines. 

    Details

CorrectSequence Therapeutics Co., Ltd. © (2021-2022)
沪ICP备2020032248号
Powered by MetInfo 7.7 ©2008-2024  mituo.cn
HOME
ABOUT
NEWS
CONTACT
XML 地图